NeuraSignal

NeuraSignal is a medical technology company focused on advanced transcranial Doppler (TCD) ultrasound systems. Originally founded as NovaSignal in 2013, the company rebranded in 2023 after acquiring NovaSignal's business. NeuraSignal aims to enhance patient care by providing clinicians with real-time cerebral hemodynamic data, which supports better diagnosis and treatment decisions. The core product is the NeuraSignal Platform, featuring the FDA-cleared NG2 Intelligent Ultrasound system and the NG View cloud-based application. This platform utilizes AI-guided robotics and advanced algorithms to automate TCD ultrasound exams, allowing hospitals to conduct cerebral blood flow assessments with improved precision and efficiency. Key features include automated depth navigation and seamless data upload for remote access, making it valuable for diagnosing cerebrovascular diseases like stroke and traumatic brain injury. NeuraSignal's technology has received multiple regulatory clearances, including FDA 510(k) and CE Mark approvals. Their products are primarily used by hospitals, stroke centers, and clinical teams in neurocritical care, empowering healthcare providers with actionable data to enhance patient outcomes.

• Employees 43
• Founded 2013
• Total Funding $63217993